Article Text

AB0033 Systemic secreted prolactin in ra leads to proinflammatory cytokine production in macrophages
  1. M. W Tang1,2,
  2. K. A. Reedquist1,2,
  3. V. Goffin3,
  4. D. M. Gerlag1,
  5. P. P. Tak1,4
  1. 1Department of Clinical Immunology and Rheumatology
  2. 2Department of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
  3. 3Research Center in Growth and Signaling, Inserm U845/Faculty of Medecine Paris Descartes, Paris, France
  4. 4Currently also GlaxoSmithKline, Stevanage, United Kingdom


Background Rheumatoid arthritis (RA) is a rheumatic disease mainly affecting women. It is known that prolactin (PRL) is a sex hormone, which apart from inducing lactation, also has immunomodulatory properties. PRL levels are elevated in the serum of both female and male RA patients compared to healthy individuals1. Furthermore, hyperprolactinemia is observed in 6% of patients with RA compared to 3% in the normal population2. It has also been observed that serum PRL levels are positively correlated with different disease parameters (eg. IgM rheumatoid factor)3. Limited open label clinical trials, using bromocriptine, leading to decreased PRL levels, show improvement in disease activity of RA patients4.

Recently the prolactin receptor (PRLR), belonging to the family of cytokine receptors, has been described in synovial tissue of RA and PsA patients, mainly on macrophages.

Objectives The objectives of this study were to unravel the mechanisms underlying the effects of PRL and its receptor in RA.

Methods PRL levels in paired serum and synovial fluid (SF) were measured using immunofluorescent metric assay in 18 patients with active RA and 12 with PsA. PRLR expression was determined by RT-PCR in monocyte-derived macrophages from healthy donors polarized with granulocyte macrophage colony stimulating factor (GM-CSF), interferon gamma (IFN-y), interleukin 10 (IL-10), macrophage colony stimulating factor (M-CSF), and RA SF. Polarized monocyte-derived macrophages were stimulated with TNF (10 ng/ml) or LPS (1 ug/ml) plus PRL (25 ng/ml) for 24 hours. Proinflammatory cytokines were measured by ELISA.

Results PRL levels were comparable in serum and SF of patients with RA, respectively 10.3 (IQR 6.0-17.6) and 10.5 (IQR 7.5-17.5) ug/L. Similar PRL levels were found in PsA patients, respectively 14.5 (IQR 8.6-18.9) and 12.5 (7.5-17) ug/L. There was a correlation between the serum PRL levels and the levels in SF (r=0.6 p=0.000), suggesting systemic production of PRL. In IFN-y and IL-10 polarized monocyte-derived macrophages, PRLR mRNA expression was 100-200 times higher (p=0.042) compared to macrophages polarized in GM-CSF, M-CSF and RA SF. IFN-y differentiated macrophages displayed a dose-dependent increase in IL-6 production afer stimulation with TNFα plus PRL and LPS plus PRL (respectively p=0.042 and p=0.000, compared to TNFα or LPS alone). Similar results were found in IL-10 differentiated macrophages.

Conclusions Our observations in SF of inflammatory joint diseases suggest systemic rather than local production of PRL. In vitro, PRLR was expressed mainly by IFN-y and IL-10 polarized monocyte-derived macrophages. Upon stimulation of these macrophages with TNFα or LPS plus PRL, a dose-dependent increase of IL-6 production was observed. These results suggests that PRL may promote inflammation in RA and PsA via enhancing macrophage activation.

  1. Orbach et al. Ann N Y Acad Sci 2007

  2. Ram et al. Rheumatology (Oxford) 2004

  3. Seriolo et al. Ann N Y Acad Sci 2002

  4. Figueroa et al. Rev Med Chil 1998

Disclosure of Interest None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.